ArticleJGH open : an open access journal of gastroenterology and hepatology2026
Stricturing Phenotype Predisposes to Small Bowel and Colorectal Malignancy in Crohn's Disease.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carcinogenesis is a major complication in patients with inflammatory bowel disease (IBD). We report the data of Crohn's disease (CD)-associated intestinal malignancy in our IBD cohort. Methods: Retrospective analysis of data from prospectively maintained medical records of 1416 CD patients diagnosed or under follow up from January 1st 2013 to December 31st 2023. Results: A total of 1416 patients were included (13037.9 person-years of follow-up with mean age at diagnosis 27.62 ± 11.8 years, 64.1% males, disease duration: 9.2 ± 6.7 years). Eighteen patients (1.27%) developed intestinal malignancy at a mean age of 46.7 ± 14.2 years after 15.9 ± 10.3 years of disease. Colorectal carcinoma (10/1416) was most frequent, followed by jejunal (4/1416), anal canal (3/1416), and ileal (1/1416) cancers. All luminal malignancies occurred in stricturing disease, while anal canal carcinoma occurred in chronic perianal fistulizing disease with anal stricture. The cumulative risk of malignancy in stricturing disease was 1.5%, 8.3%, and 25.1% in the first, second, and third decades of disease, respectively. Independent risk factors included older age at CD diagnosis, longer disease duration, stricturing phenotype, and active smoking. The standardized incidence ratio (SIR) for intestinal malignancy was 95.36 (95% CI: 52.98-143.04), nearly 95-fold higher than the general population. Conclusion: The incidence rate of intestinal malignancy was 1.27% in our CD cohort with standardized incidence rate of 95.3. Stricturing disease predisposed to small bowel and colorectal carcinoma. Carcinoma in anal canal was seen in chronic perianal fistulizing disease with anal canal stricture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.